Objective: To evaluate the hepatoprotective activity of Clearliv a polyherbal formulation in Wistar rats. Materials and Methods: The hepatoprotective potential of Clearliv was evaluated in thioacetamide-induced liver necrosis, DL-galactosamine [GalN]-induced liver injury, and carbon tetrachloride [CCl 4 ]-induced hepatitis models in Wistar rats. In all the models, Clearliv (at the dose levels of 800, and 1000 mg/kg) was administered for 3 days orally followed by single intraperitoneal administration of the hepatotoxicant on the last day after one hour of Clearliv administration. After 24 h of toxicant administration blood sample was collected by sino-orbital puncture in sodium EDTA tubes. The effi cacy of Clearliv was evaluated by plasma biochemical parameters (AST, ALT, and ALP), and antioxidant enzyme (lipid peroxidation, catalase, superoxide dismutase, glutathione peroxidase, and hydroxyproline) levels. Results: In thioacetamide-induced necrosis, and GalN-induced liver injury models, Clearliv at 1000 mg/kg showed signifi cant reduction in the elevated plasma liver markers, and elevated antioxidants levels. In CCl 4 -induced hepatitis, the Clearliv had favorable hepatoprotective effect, but the results were not signifi cant. Conclusion: Clearliv 800, and 1000 mg/kg showed signifi cant hepatoprotective effect against thioacetamide-and GalN-induced liver necrosis and injury, respectively.
Introduction
In the recent years, due to vast amount of scientific ethnopharmacological work carried out on herbs with claims of curative properties by folklore or traditional or by indigenous system of medicine, interest on the efficacy, and safety of the medicinal herbs has generated tremendous interest in the scientific community, pharmaceutical companies, and in general by the common man. [1] Due to this, several polyherbal products have come into the market claiming to have ingredients formulated based on the indigenous system of medicine in India. Ayurvedic system of medicine is a traditional Indian system of medicine, and it has been practiced for several centuries. Ayurveda system of medicine has been gaining acceptance in the Western countries because of the side-effects at the time associated with allopathic drugs. [2] In recent years, several pharmaceutical companies are involving in ayurvedic research to develop effective ayurvedic formulations. Clearliv is a marketed polyherbal formulation which claims that it can be used for the treatment of hepatic necrosis, hepatitis, and liver injuries. Hence, the present study was undertaken to determine the hepatoprotective effect Clearliv using chemical (thioacetamide, DL-galactosamine
The test substances, and standard drug were dissolved in distilled water, and they were administered once daily (p.o.) for 3 days. The normal and thioacetamide control animals were received distilled water at the dose of 1 ml/kg. Group-III to V animals were received Liv-52 (20 ml/kg), Clearliv 800 mg/kg, and Clearliv 1000 mg/kg, respectively. After one hour of last dose of vehicle/ drug administration, the animals of groups II to V were administered a single intraperitoneal injection of thioacetamide at a dose of 500 mg/kg. After 24 h of thioacetamide injection, the blood was drawn from all groups through sino-orbital puncture in sodium EDTA tubes under light diethyl ether anesthesia. [7] The plasma was separated by centrifuging the blood sample at 2,000 RPM for 20 min, and the plasma was used for estimation of aspartate transaminase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total protein, and albumin. At the end of the experiment, the animals were sacrificed by cervical dislocation, and the liver was excised out, and stored in -70ºC deep freezer until estimation of lipid peroxidation, and enzymatic antioxidants such as catalase, superoxide dismutase, glutathione peroxidase, and hydroxyproline. [8] Effect of Clearliv on GalN-induced liver injury in female Wistar rats The rats were divided into five groups of six animals each as follows.
Group-I: Normal control Group-II: GalN control Group-III: Liv-52 20 ml/kg Group-IV: Clearliv 800 mg/kg Group-V: Clearliv 1000 mg/kg
The test substances, and standard drug were dissolved in distilled water, and they were administered once daily (p.o.) for 3 days. The normal and GalN control animals were received distilled water at the dose of 1 ml/kg. Group-III to V animals received Liv-52 (20 ml/kg), Clearliv 800 mg/kg, and Clearliv 1000 mg/kg respectively. After one hour of last dose of vehicle/ drug administration, the animals of groups II to V were administered a single intraperitoneal injection of GalN at a dose of 400 mg/kg. After 24 h of GalN injection, the animals were anesthetized, and blood sample was collected in sodium EDTA tubes, and plasma was separated. [7] The plasma sample was used for analysis of biochemical parameters such as AST and ALT. At the end of the experiment, the animals were sacrificed by cervical dislocation, and the liver was excised out and stored in -70ºC deep freezer until estimation of lipid peroxidation and catalase. [9, 10] Effect of Clearliv on carbon tetrachloride-induced hepatitis in female Wistar rats The rats were divided into five groups of six animals each as follows.
Group-I: Normal control Group-II: CCl 4 control Group-III: Liv-52 (20 ml/kg) Group-IV: Clearliv 800 mg/kg Group-V: Clearliv 1000 mg/kg The test substances, and standard drug were dissolved in distilled water, and they were administered once daily (p.o.) for 3 days. The normal and CCl 4 control animals were received distilled water at the dose of 1 ml/kg. Group-III to V animals received Liv-52 (20 ml/kg), Clearliv 800 mg/ kg, and Clearliv 1000 mg/kg respectively. After one hour of last dose of vehicle/ drug administration, group II to V animals were administered a single intraperitoneal injection of CCl 4 at a dose of 50 l/kg. After 24 h of CCl 4 injection, the animals were anesthetized, and blood sample was collected in sodium EDTA tubes, and plasma was separated. [7] The plasma sample was used for analysis of biochemical parameters such as AST, and ALT. [11, 12] Estimation of enzyme levels in plasma The plasma liver markers such as AST, ALT, ALP, total protein, and albumin were estimated using semi-autoanalyzer (M/s Vital Scientific N.V., The Netherlands). The biochemical kits for AST, ALT, ALP, total protein, and albumin were obtained from E. Merck (India) Pvt. Ltd.
Estimation of biological parameters of liver tissue
The liver tissue was washed thoroughly in ice-cold saline to remove the blood after thawing, blotted the saline gently using filter paper, and homogenized with 50 mM tris-HCl. [13] The lipid peroxidation levels in liver tissue were estimated using modified Ohkawa method. [14] To 0.2 ml liver tissue homogenate, 0.3 ml of 0.005% butylated hydroxytoluene (BHT) in methanol, and 2.1 ml of thiobarbituric acid were added. The mixture was incubated at 90ºC for 45-60 min. Later on, the mixture was centrifuged at 4000 rpm for 10 min. The red chromogen supernatant layer was measured at 532 nm. The levels were expressed as moles of MDA/g of tissue. Tetra ethoxy propane was used as external standard for lipid peroxidation assay.
The liver catalase activity was estimated using available literate elsewhere. [15] To 100 l liver homogenate, 2.25 ml of potassium phosphate buffer, and hydrogen peroxidase (catalyst) was added. The mixture was incubated at 25ºC for 30 min. The change in absorbance at 240 nm was measured for 2-3 min in UV-visible spectrophotometer. The dy/dx for every 30 second for each assay was calculated, and the results were expressed as catalase units of protein.
Catalase in 100 l of sample was calculated using formula (dy/dx × 0.0003)/ (38.3956 × 10 6 ).
The liver glutathione peroxidase (GSH-Px), and superoxide dismutase (SOD) were estimated using kits (Randox Diagnostic Kit, Ranbaxy Laboratories, India) according to the manufacturers' instructions. Results of GSH-Px, and SOD levels were expressed as mU/mg of protein, and SOD Units/ mg, respectively.
Hydroxyproline in the liver homogenate was estimated using available literate elsewhere. [16] To 100 l of liver homogenate, 1900 l of assay buffer (composition: citric acid, glacial acetic acid, sodium acetate, sodium hydroxide, and toluene as preservative), 1 ml of chloramine-T was added, and incubated at room temperature for 20 min. In that reaction, mixture 1 ml of 3,3-Diaminobenzidine (DAB) was added, and again incubated at 60ºC for 15 min. Later on, the reaction mixture was allowed to cool, and the absorbance was measured at 550 nm. The results was expressed as g of Hydroxyproline/ g of tissue.
Total protein was estimated by the procedure described by Lowry et al. [17] To 50 l of liver homogenate, 450 l of 0.5N sodium hydroxide, and 500 l of 10% trichloroacetic acid was added. It was centrifuged at 4000 RPM for 10 min, and supernatant was discarded. The sediment was reconstituted with 500 l of 0.5N sodium hydroxide and incubated at 60ºC for 10 min. Later on, 2 ml of alkaline cuprate tartarate, and 250 l 2N Folins reagent were added. The blue color formed was measured at 540 nm, and the results were expressed as mg of protein/ g of tissue. The protein calibration curve was prepared using bovine serum albumin (10 mg/ml stock).
Statistical analysis
All the vales are mean ± SEM. Significant difference between groups were determined using one-way ANOVA followed by Tukey's multiple comparison test. The statistical analysis was calculated using GraphPad Instat 3.06 (GraphPad Software, CA). A P value less than 0.05 was considered to be significant.
Results
In thioacetamide-, GalN-, CCl 4 -induced hepatotoxicity models, toxins are not having any influence on alterations in body weight. No significant alterations in body weight were observed in both treatment, and toxin-administered groups when compared to normal control group. The toxin-administered groups showed significant increases in biochemical and liver tissue homogenate oxidative parameters (P < 0.01) compared to normal control group. The effects of Clearliv on liver enzymes and oxidative parameters were summarized in Tables 1-4. In thioacetamide-induced necrosis, Clearliv at a dose of 1000 mg/kg showed significant reduction in the elevated plasma AST, ALT, ALP levels, and liver lipid peroxidation levels compared to thioacetamide control group. Thioacetamide-administered group showed significant increase in hyroxyproline levels, and decreased SOD, catalase, and GSH-Px levels compared to all other treatment group. Effect of Clearliv on plasma biochemical and liver tissue homogenate oxidative parameters in thioacetamide-induced necrosis rat was presented in Tables 1 and 2 .
In GalN-induced necrosis, Clearliv 1000 mg/kg significantly reduced the plasma AST, ALT levels, liver lipid peroxidation level and catalase levels compared to GalN control group. Effect of Clearliv on plasma biochemical and liver tissue homogenate oxidative parameters in GalN-induced necrosis was presented in Table 3 .
In CCl 4 -induced hepatitis, Clearliv 1000 mg/kg showed significant decrease in ALT levels. But Clearliv 800 and 1000 mg/kg does not reverse the CCl 4 -induced increase in AST levels. Effect of Clearliv on plasma biochemical parameters in CCl 4 -induced necrosis was presented in Table 4 . The biochemical alterations concluded that the Clearliv does not reverse the CCl 4 -induced hepatitis in rats.
Discussion
Clearliv at the dose levels of 800 and 1000 mg/kg showed a significant hepatoprotective effect against thioacetamideand GalN-induced hepatotoxicity in rats. The preliminary acute toxicity (fixed dose procedure) study was carried out to determine the dose of Clearliv for pharmacological study. [18] A single oral dose toxicity study of Clearliv did not showed any toxic signs upto 2000 mg/kg in female rats.
Clearliv 1000 mg/kg significantly reduced the elevated levels of AST, ALT, and ALP produced by a single dose administration of thioacetamide. With respect to its antioxidant levels, Clearliv 1000 mg/kg showed a significant reduction in lipid peroxidation level, and elevation of glutathione peroxidase, superoxide dismutase, and catalase levels. Thus, it could be suggested that Clearliv with its free radical scavenging property has hepatoprotective activity in this model, which was further supported by reduced levels of hydroxyproline in liver tissue homogenate. Free radicals generated by thioacetamide oxidation also lead to cell death; it could be suggested that Clearliv may reduce the cell permeability, and thus offering protection against thioacetamide.
In GalN model, Clearliv 1000 mg/kg significantly reduced the levels of AST, ALT produced by single administration of GalN with respect to its antioxidant levels. Clearliv at 1000 mg/ kg showed a significant reduction in lipid peroxidation, and elevation of catalase. Thus, it could be suggested that Clearliv 
P<0
.001 as compared to normal (one-way ANOVA followed by Tukey's test), *P<0.05, *P<0.01, *P<0.001 as compared to thioacetamide (one-way ANOVA followed by Tukey's test) has hepatoprotective activity in this model by stabilization of the cell membrane from oxidative stress.
In CCl 4 -induced hepatitis, Clearliv at 1000 mg/kg showed significant reduction in ALT levels, but did not produce significant reduction of AST levels.
Thioacetamide is used as a fungicide, and also it is a potent hepatotoxicant. [17] In thioacetamide-induced liver necrosis is initiated by biotransformation of thioacetamide by the microsomal FAD monooxygenase system. [19] Thioacetamide is bioactivated by CYP2E1 to thioacetamide sulfoxide and thioacetamide sulfodioxide, which are the penultimate and ultimate reactive metabolite that are responsible for [20] the liver injury by oxidative stress, lipoperoxidation, [21] increase in the cytosolic calcium and changes in DNA ploidy and distribution in the cell cycle phases, thereby leading to centrilobular necrosis. [22] GalN-induced hepatotoxicity is one of the most widely employed models for studying liver injury. Single dose of GalN (500 mg/kg. i.p.) produces liver injury. [9] The metabolite of D-GaLN namely uridine phosphogalactosamine may deplete several uracil nucleotides such as UDP-galactose, UDP-glucose, and UTP causing reduction of mRNA and glycoprotein synthesis (reduction of ATP and glycogen synthesis), which leads to cellular membrane alteration. [23] CCl 4 mainly acts by the generation of free radicals and increases the lipid peroxidation disturbing membrane integrity and function and thus producing liver damage. [24] Clearliv fails to produce hepatoprotective activity in CCl 4 model; this may be due to its poor capability in preventing the lipid peroxidation. This may not be the case of GalN-or thioacetamide-induced liver injury and necrosis, as the damage caused by the agents are most probably due to perturbation of Ca ++ and inhibition of mRNA and protein synthesis. In liver tissues, AST, and ALT are found in higher concentrations in cytoplasm and AST, in particular, also exists in mitochondria. In liver injury, membrane damage is caused to the plasma membrane of mitochondria and endoplasmic reticulum, which leads to the leakage of AST, ALT, and reduction in protein transportation, thereby decreasing the antioxidants, which further aggravates the liver damage impeding their regulatory metabolic function. [25] It could be suggested that Clearliv affords hepatoprotective activity by a consequence of stabilizing membranes of mitochondrial, endoplasmic reticulum, and by its moderate antioxidant activity.
The individual herb of Phyllanthus niruri, Eclipta alba, Boerhaavia diffusa, Andrographis paniculata, and Tinospora cordifolia have been evaluated for its hepatoprotective activity in various animal models. Eclipta alba at a dose of 50 mg/kg was studied in CCl 4 -, paracetamol-, and aflatoxininduced hepatic injury, and has shown hepatoprotective activity by reducing the serum AST, and ALT. [26] Another study showed that Phyllanthus niruri at a dose of 50, 100 mg/kg reversed the biochemical and histopathological changes against paracetamol-induced liver damage in mice. [27] However, it was noted that the hepatoprotective activity of Clearliv was seen only at the doses of 800 and 1000 mg/kg, which could be considered as a high therapeutic dose levels, including polyherbal formulations like HD-03. [9] The reason could be that the stability, efficacy, and potency of various ingredients in polyherbal formulation depend on several factors such as time of collection of plants, storage period, self-life, and adequate standardization, which could affect efficacy of polyherbal formulation.
Therefore, it could be suggested that phytochemical studies could be performed based on the known markers for the raw material, and latter extended to the formulation, which may provide an insight to the lack of efficacy of this polyherbal formulation. Synergy is considered to be a key word with respect to the therapeutic activity of herbs. [28] This aspect is to be proved or studied in depth, which is beyond the scope of the present study. Nevertheless, the present study reveals the potential of Clearliv with respect to its hepatoprotective activity, especially in thioacetamide-induced necrosis model, and GalN-induced liver dysfunction.
Conclusion
Clearliv at 800 and 1000 mg/kg showed a significant hepatoprotective action against various hepatotoxicantinduced liver necrosis, and injury. 
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